Logo

APVO

Aptevo Therapeutics Inc.

APVO

Aptevo Therapeutics Inc. • NASDAQ
$1.38 ▲ 7.81% (+0.10)
Market Cap $40.81 M
52w High $298.00
52w Low $1.04
Dividend Yield 0%
P/E 0
Volume 553.19K
Outstanding Shares 16.85M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $7.61M ▲ $-7.549M ▼ 0% $-2.23 ▲ $-7.5M ▼
Q2-2025 $0 $6.226M ▼ $-6.204M ▲ 0% $-8.4 ▲ $-6.177M ▲
Q1-2025 $0 $6.48M ▲ $-6.408M ▼ 0% $-87.87 ▼ $-6.419M ▼
Q4-2024 $0 $6.311M ▲ $-6.312M ▼ 0% $-86.56 ▲ $-6.311M ▼
Q3-2024 $0 $5.213M $-5.101M 0% $-357.85 $-5.129M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $21.061M ▲ $26.996M ▲ $9.604M ▲ $17.392M ▲
Q2-2025 $9.41M ▲ $15.624M ▲ $9.1M ▼ $6.524M ▲
Q1-2025 $2.139M ▼ $8.342M ▼ $9.815M ▼ $-1.473M ▼
Q4-2024 $8.714M ▲ $15.591M ▲ $10.836M ▲ $4.755M ▲
Q3-2024 $7.753M $15.146M $10.726M $4.42M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-7.549M ▼ $-6.688M ▲ $0 $18.339M ▲ $11.651M ▲ $-6.688M ▲
Q2-2025 $-6.204M ▲ $-7.093M ▼ $0 $14.364M ▲ $7.271M ▲ $-7.093M ▼
Q1-2025 $-6.408M ▼ $-6.575M ▼ $0 $0 ▼ $-6.575M ▼ $-6.575M ▼
Q4-2024 $-6.312M ▼ $-5.759M ▼ $0 $6.72M ▲ $961K ▲ $-5.759M ▼
Q3-2024 $-5.101M $-5.222M $0 $4.909M $-313K $-5.222M

Revenue by Products

Product Q2-2018Q3-2018Q4-2018
Product
Product
 $10.00M ▲$10.00M ▲$10.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Aptevo looks like a classic early‑stage biotech on the income side: there is essentially no product revenue, and the company has been running steady operating losses for years. The losses mainly reflect ongoing research and clinical spending rather than a commercial business. There was a brief period where reported profit flickered positive, which likely reflects one‑off items or accounting effects, not a sustainable turnaround. Overall, the business is still firmly in the “investment phase” where money is being spent to develop drugs, not yet earned from selling them.

Balance Sheet

Balance Sheet The balance sheet is small and dominated by cash, with only modest other assets, which fits an R&D‑focused biotech without manufacturing plants or large physical assets. Debt has been present but not overwhelming, although the company’s equity base has swung around, suggesting repeated fundraisings and recapitalizations. The series of reverse stock splits over several years signals pressure to maintain listing standards and points to meaningful shareholder dilution over time. Financially, this is a lean, high‑risk balance sheet that depends heavily on continued access to capital markets or partners.

Cash Flow

Cash Flow Cash flow is consistently negative, driven by operating losses from research and clinical trials. There is essentially no spending on big long‑term assets, so cash burn is almost entirely tied to people, trials, and platform development. This means Aptevo can, in principle, slow spending if needed, but progress would also slow. The stated cash runway into late 2026 offers some breathing room, yet the company still relies on either future financings, partnerships, or milestone payments to fund operations beyond that.

Competitive Edge

Competitive Edge In competitive terms, Aptevo is a very small player operating in a field crowded with large, well‑funded pharmaceutical and biotech companies. Its edge lies in specialized bispecific and trispecific antibody platforms designed for better safety and dosing convenience, particularly the effort to reduce severe immune‑related side effects. Targeting difficult cancers with high unmet need gives the company a clear medical focus and potential for meaningful impact if trials succeed. However, its limited size, lack of commercial products, and the presence of large incumbents mean its competitive position is promising but fragile and highly dependent on clinical data and partnerships.

Innovation and R&D

Innovation and R&D Innovation is the core strength here. Aptevo has built a versatile antibody engineering platform (ADAPTIR and ADAPTIR‑FLEX) and is applying it across several cancer programs, from blood cancers like AML to challenging solid tumors. Early clinical signals from its lead programs highlight the potential for strong responses with a cleaner safety profile, which is a key differentiator in immuno‑oncology. A pipeline of next‑generation trispecific antibodies and an existing collaboration with another biotech show that the platform is designed for both breadth and partnering potential. The flip side is that most assets are still early or mid‑stage, so scientific and regulatory uncertainty remains high.

Summary

Aptevo is a small, clinical‑stage cancer biotech that is long on scientific ambition and short on commercial maturity. Financially, it has minimal revenue, ongoing losses, steady cash burn, and a history of reverse splits and dilution, reflecting the typical risk profile of early‑stage drug developers. Strategically, its strength is a differentiated antibody platform aimed at safer, more flexible immunotherapies, with encouraging early trial results and multiple “shots on goal” in its pipeline. The company’s future hinges on three things: continued positive clinical data, the ability to secure supportive partnerships, and effective management of its limited financial resources. For observers, this is a high‑risk, high‑uncertainty story driven far more by science and trial outcomes than by current financial performance.

NEWS

November 10, 2025 · 8:05 AM UTC

Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors

Read more

November 6, 2025 · 8:05 AM UTC

Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update

Read more

October 8, 2025 · 8:20 AM UTC

Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter

Read more

September 16, 2025 · 8:30 AM UTC

Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML

Read more

September 4, 2025 · 8:45 AM UTC

Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules

Read more